Resource Center
RDPAC Announces Update to Vice Chair for 2024-2025 Executive Committee
20/09/2024
The 2024-2025 RDPAC Executive Committee updates are now complete.
Welcome, Ping An-Shionogi!
01/07/2024
RDPAC EC voted to approve the application of Ping An-Shionogi to join RDPAC as of July 1, 2024.
RDPAC Announces Update to Executive Committee for 2024-2025 Term
29/12/2023
Cecilia Qi will join RDPAC Executive Committee and sever a tenure of two years.
In China, for China and for global, assisting China to fully integrate into the simultaneous global R&D system for innovative drugs——RDPAC R&D Working Group 2023 Annual Meeting, Shanghai
26/12/2023
The RDPAC R&D Working Group (WG) held its 2023 annual meeting in Shanghai on 7 December.
RDPAC Announces New Chair and Vice-Chairs of the 2024-2025 Executive Committee
23/10/2023
RDPAC officially announces the new Chair and Vice-Chairs of the Executive Committee for the 2024-2025 term.
RDPAC was Invited to Participate in the NMPA's "2023 ICH in China: Progress and Outlook Symposium"
07/10/2023
NMPA held 2023 ICH in China: Progress and Outlook Symposium in Beijing on September 12.
RDPAC Announces New Executive Committee Members for 2024-2025
28/09/2023
RDPAC is pleased to announce the list of members for the new executive committee for the term 2024-2025.
The International Biopharmaceutical Industry Innovation Conference Beijing Forum and the Special Forum on ICH Guidelines for Clinical Trails held in Beijing
28/09/2023
On September 7, 2023, the“1st IBIIC•BJF” convened in the Beijing Economic-Technological Development Zone.
RDPAC announces the appointment of Mr. Renaud GABAY as Managing Director； Madam KANG Wei will continue to contribute with her expertise as Executive Advisor
25/09/2023
Mr. Renaud GABAY will assume the role of Managing Director of RDPAC, effective October 1, 2023.
2023 China Joint Strategy Session is Successfully Convened in Beijing
20/09/2023
On September 13, the 2023 China Joint Strategy Session (JSS) was co-hosted by RDPAC and PhRMA
RDPAC Code of Practice
17/11/2022
A major requisite for innovation is integrity, which is also the foundation of reputation. Without ethical decision-making, there is no true innovation.
RDPAC Announces Membership Succession of Executive Committee 2022-2023
25/05/2022
The R&D-based Pharmaceutical Association Committee (RDPAC) has announced a change in membership of the RDPAC Executive Committee 2022-2023.
Paying for Innovation to Secure Payback - To Build a Value-oriented Innovative Payment System
22/04/2022
The 2022 Jinling Pharmoeconomics Forum and the Annual Conference of Pharmoeconomics Committee, Jiangsu Pharmaceutical Association were held online on April 16-17.
Developing an Innovative Multi-Layered Security System for Rare Diseases Drugs and Establishing a Drug Value Assessment Mechanism
23/12/2021
Healthcare Security Policy Sub-Forum of 2021 China Conference on Rare Diseases Successfully Held
RDPAC Successfully Held Global R&D Leaders Webinars MNCs CSO Leaders Discussed Opportunities and Challenges for Global Simultaneous Research & Development in China
01/12/2021
On Nov. 9th and 10th, 2021, the R&D-based Pharmaceutical Association Committee (RDPAC) held virtual “Global R&D Leaders Webinars”.
Joining Together – Building a New Future for China's Pharma Innovation Ecosystem
09/11/2021
the press conference "Joining Together – Building a New Future for China's Pharma Innovation Ecosystem" was held at the 4th China International Import Expo (CIIE).
RDPAC Announces New Leadership of Executive Committee 2022-2023
18/10/2021
The R&D-based Pharmaceutical Association Committee (RDPAC) announces its new Chairman and Vice Chairmen for RDPAC Executive Committee 2022-2023.
RDPAC Announces 13-New Executive Committee Members for 2022-2023
24/09/2021
Beijing, September 24, 2021 – The R&D-based Pharmaceutical Association Committee (RDPAC) announces a great news on its newly-elected Executive Committee Members for 2022-2023.
“The 4th Sub-report of Fostering China Pharmaceutical Innovation System: Promote Simultaneous R&D, Registration and Review of Innovative Drugs” Released
15/09/2021
Through joint efforts of PhIRDA and RDPAC, the “Fostering China Pharmaceutical Innovation System Report 4: Promote Simultaneous R&D, Registration and Review of Innovative Drugs” is officially released today.
The 3rd Sub report of Fostering China Pharmaceutical Innovation System: Multi-layered Healthcare Security System to Improve People’s Health and Drive High-quality Industrial Development Released
19/08/2021
On 16th August, the 3rd sub-report of Fostering China Pharmaceutical Innovation System: Multi-layered Healthcare Security System to Improve People's Health and Drive High-quality Industrial Development was released through joint efforts by PhIRDA and RDPAC
2021 PhRMA -RDPAC Joint China Strategy Session Successfully Held
07/07/2021
PhRMA and RDPAC, together with EFPIA, JPMA and BIO, co-hosted the annual Joint China Strategy Sessions on Science/Regulatory, Intellectual Property and Market Access.
RDPAC Prospect: Three Starting Points of Innovative Drugs for a Healthy China—Release of the Report on Innovation in Pharmaceutical Industry for a Healthy China
11/03/2021
On the occasion of the Two Sessions, China Association of Enterprises with Foreign Investment R&D-based Pharmaceutical Association Committee (RDPAC) released the Report on Innovation in Pharmaceutical Industry for a Healthy China
Health, Innovation, Cooperation——Two Sessions’ Voice from Heads of 24 Multinational Pharmaceutical Enterprises in China
05/03/2021
Heads of RDPAC’s 24 multinational pharmaceutical companies in China, on behalf of the pharmaceutical industry, called upon the government, businesses, universities, and research institutes to cooperate, improve relevant policies and strengthen their implementation from diverse areas and to bring practical benefits to patients in China.
A Gift to 2021|"Building China's Pharmaceutical Innovation Ecosystem-Part One of the Series: 2015-2020 Development Review and Future Prospects" is officially released
04/03/2021
On March 2, 2021, PhIRDA and RDPAC jointly released "Building China's Pharmaceutical Innovation Ecosystem-Part One of the series research reports: 2015-2020 Development Review and Future Prospects"
Listen to Asgar’s "Key Points"-at RDPAC 2021 Town Hall Meeting
09/02/2021
Chairman of the RDPAC Executive Committee, came to the RDPAC Beijing office to extend holiday greetings to all RDPAC staff.
Focus on Global Simultaneous Development and Talent Development
05/01/2021
On December 18, 2020, the annual meeting of RDPAC R&D Committee was grandly held on the Roche Pharma Shanghai campus.
Innovation and Collaboration for Healthy China- RDPAC and its Member Companies Made a Wonderful Appearance at the CIIE
18/11/2020
The “Innovation and Collaboration for Healthy China” conference given by RDPAC was solemnly held in the Medical Devices and Medical Care exhibition area of the China International Import Expo.
Improving China’s pharmaceutical innovation ecosystem and jointly contributing to a Healthy China
09/10/2020
On September 27, 2020, the 5th China BioMed Innovation and Investment Conference was held in Suzhou Industrial Park.
RDPAC Members about to Show Innovative Achievements in the 3rd China International Import Expo
30/07/2020
As the leader of global pharmaceutical innovation, RDPAC member companies will continue to show their global innovative achievements in the 3rd CIIE.
Four Keywords of Two Sessions that KANG Wei focused on
08/06/2020
Recently, KANG Wei, Managing Director of R&D-Based Pharmaceutical Association Committee (RDPAC) received an exclusive interview from Chinese Pharmaceutical News on hot topics that she cared about during the two sessions.
22 Pharmaceutical MNC Leaders' Messages to the Two Sessions
03/06/2020
Two sessions were finally held after the outbreak, at this special historical moment, the China leader of RDPAC 22 member companies have shared their views
Let the drugs no longer be “rare” ——RDPAC and CHARD jointly support innovation and availability of drugs for rare diseases
27/04/2020
R&D-Based Pharmaceutical Association Committee (RDPAC) and China Alliance of Rare Diseases (CHARD) have established a long-term partnership, and jointly initiated a research on Medical Insurance Access and Payment Mechanism and Impact on Basic Medical Insurance Fund of Rare Disease Drugs in China
Drug Innovation: Making Cancer A Chronic Disease
24/04/2020
April 15-21 this year is the 26th National Cancer Prevention and Control Week in China. The Bureau of Disease Prevention and Control of the National Health Commission (NHC) called on the whole society and the pharmaceutical industry, on the theme of “Joint Action for Cancer Prevention and Control”
IPIF2020 Cancellation Notice
01/04/2020
In view of the current severe situation of COVID-19 in the world, the organizing committee has decided to cancel the International Pharmaceutical Innovation Forum 2020 (IPIF 2020).
Commitment to Overcoming Current Difficulties in Wuhan——RDPAC Member Companies in Action
23/02/2020
As of March 12, 2020, more than 35 RDPAC member companies have donated cash and medical supplies with a total value of more than RMB 190 million
Pharmaceutical Innovation for Healthier China: the 2nd International Pharmaceutical Innovation Forum was Held in Beijing
02/01/2020
(Beijing, March 26, 2019) Today, key stakeholders and thought leaders in the pharmaceutical industry gathered in Beijing for the 2nd International Pharmaceutical Innovation Forum (IPIF19)
Kang Wei: Establishing Patient-Centered Code of Ethics for Pharmaceutical Industry
02/01/2020
On October 10, 2019, Kang Wei, Managing Director of RDPAC, gave a speech on the theme of “Code of Ethics for Pharmaceutical Industry - a Shi
197 Drugs for COPD and Asthma are in Development to Meet the Challenges of Chronic Respiratory Diseases
02/01/2020
RDPAC releases Faces of Innovation: Meeting the Challenge of Chronic Respiratory Diseases report
RDPAC Announces Interim Leadership Structure
26/02/2019
RDPAC announced its interim Executive Committee Bureau.
2019 International Pharmaceutical Innovation Forum to Take Place in Beijing
10/09/2018
Recognizing China’s growing status in global pharmaceutical innovation, IPIF19 will bring together public and private stakeholders from acro
Madam KANG Wei to Lead RDPAC as New Managing Director
27/02/2018
[ Beijing, Feb 27, 2018] ---R&D-Based Pharmaceutical Association Committee (RDPAC) today announced that Madam KANG Wei will take the role of
7 institutions call for clinical research development, to eliminate innovation bottlenecks in China’s pharmaceutical industry
05/01/2018
Today, seven institutions jointly released the research report titled Deepening the drug innovation ecosystem reform -- A plan to design and
RDPAC Announces New Leadership
15/12/2017
On December 14th, The R&D-based Pharmaceutical Association Committee (RDPAC) announced its new Executive Committee Members.
Diabetes Treatment Success Rates less than 50%, Drugs Are in Urgent Need of Innovation to Deal with the Challenges of Diabetes
14/11/2017
During the 26th “World Diabetes Day” approaching, RDPAC released 2017 report Meet the Challenges of Diabetes with Drug Innovation in Shangha
RDPAC Reaffirms MOU with BIO
04/07/2017
On 19 June 2017 Joe Damond, Executive Vice President of BIO, signed a Memorandum of Understanding for Cooperation (MOU) with Mr. Mike Dethic
Mr. Chen Deming：The continued innovation of new drugs for the health of our people will only be possible with the protection of the intellectual property rights of pharmaceutical manufacturers
20/04/2017
We have just ended Two Sessions this year, where Premier Li Keqiang made special mention regarding the health of the people, and 2,000 repre
Ten industry associations endorse Declaration for Pharmaceutical Innovation at 2017 International Pharmaceutical Innovation Forum (IPIF)
22/03/2017
22 March 2017 –NANJING: Ten leading domestic and foreign trade associations signed and endorsed the Declaration for Pharmaceutical Innovatio
RDPAC Announce the 2017 International Pharmaceutical Innovation Forum 22-23 March to be Held in Nanjing
21/01/2017
On January 19, a press conference for the 2017 International Pharmaceutical Innovation Forum (IPIF) was successfully held in Nanjing, China.
An Average of 80% of Drug in the Oncology Pipeline May Be First-in-Class Medicines
19/01/2017
With the 16th “World Cancer Day” approaching on February 4, the R&D Based Pharmaceutical Association Committee of the China Association of
Over 170 kinds of diabetes drugs are under research to deal with the challenge of diabetes
11/11/2016
With the coming of the 25th “World Diabetes Day”, R&D Based Pharmaceutical Association Committee of China Association of Enterprises with Fo
Fostering a Sustainable Ecosystem for “Healthy China 2030”
31/10/2016
Innovation-driven development is a core strategy of China’s “13th Five-Year (2016-2020) Plan” and biomedicine is a key driver of that innova
Four Associations Signed Memorandum of Understanding to Promote the Professionalization and Formal Management of Medical Representatives
28/06/2016
Tuesday June 28, 2016, Beijing: the 2016 Pharmaceutical Enterprises Ethical Business Practices China Forum jointly organized by 17 pharmaceu
Gathering for a New Starting Point of Career Development for Medical Representatives
26/01/2016
“China Symposium for Pharmaceutical Industry Self-regulation and Career Management and Development of Medical Representatives” was held in B
40% of Increases in Global Per Capita Average Life
29/12/2015
The R&D-based Pharmaceutical Association Committee under the China Association of Enterprise with Foreign Investment (RDPAC) published the r
17 Associations Endorsed Pharmaceutical Enterprise
30/06/2015
The 2015 China Forum on Ethical Business Practices for Pharmaceutical Enterprises jointly organized by nine pharmaceutical industry associat
Growing support for shared ethical principles from healthcare and medicines providers
27/01/2015
The International Hospital Federation (IHF) and the International Generic Pharmaceutical Alliance (IGPA) endorse efforts by organizations re
China Forum on Ethical Business Practices for Pharmaceutical Industry Held in Beijing
27/05/2014
To further promote the implementation of the Ethical Codes for Pharmaceutical Companies (hereinafter the Codes), strengthen the building of
The Essential Drug System Helped on Burden Alleviation but Still Need Improvement
12/02/2014
A survey on 30 city- and county-level grass-roots medical institutions shows, after implementation of essential drug system, the average fee
Pharmaceutical Enterprises are Prepared to Green
12/02/2014
At the 15th Environment, Health and Safety (EHS) Working Group Meeting held by R&D-based Pharmaceutical Association Committee of CAEFI (RDPA
The Role of Medical Representatives Are Recognized by Clinicians
12/02/2014
Chinese Medical Doctor Association (CMDA) held a workshop on the survey results of “Cognition Degree of Clinicians on Specialization Degree
120 innovative anti-diabetes medicines in development by RDPAC members
12/02/2014
97 innovative medicines to treat type 1 and type 2 diabetes lies in the pipeline of RDPAC member companies with another 23 in development to
R&D Pharmaceutical Enterprises Advocate to Reduce Carbon Footprint of Drug Use
12/02/2014
On October 20, 2010, the 13th Environment, Health and Safety Working Group Meeting was held by R&D-based Pharmaceutical Association Committe
RDPAC Issues “Pharmaceutical Quality Study Report”
12/02/2014
R&D-based Pharmaceutical Association Committee of CAEFI (RDPAC) issues the “Pharmaceutical Quality Study Report”. For the purpose to make Ch
R&D Based Pharmaceutical Enterprises Advocate Sustainable Business Operations
12/02/2014
China, as a rapidly growing emerging economy, should give equal attention to the demand of offspring development while meeting the ever-incr
Ten years after Entry into WTO Witness the Number
12/02/2014
According to the statistical presentation of R&D-based Pharmaceutical Association Committee of CAEFI (RDPAC), among 37 RDPAC member companie
To Promote Safe Use of Medicines for the Public Through Bringing the Strengths and Resources of All Society into Full Play —— Establishment of the Partnership for Safe Medicines China
12/02/2014
The National “Twelfth Five-Year Plan” for Drug Safety specifically states that drug safety is an issue that concerns people’s welfare and pu
Welcome, Mayoly!
27/12/2024
RDPAC EC voted to approve the application of Mayoly to join RDPAC as of January 1, 2025.
RDPAC-HKAPI Guidance on Interactions with Hospitals, HCPS and Patients under the Greater Bay Area“Hong Kong & Macau Registered Medicine Access to GBA Program”
2024.01
Download
(4.36)
RDPAC Digital Health Compliance Sub-Guidance: Interactions with Patients & Patient Organizations
2024.01
Download
(1.37MB)
RDPAC Digital Health Compliance Sub-Guidance: Interactions with HCPs & HCOs
2024.01
Download
(1.34MB)
Research Report on the Sustainable Development of City Supplementary Commercial Health Insurance in China
2022.10
Download
(2.39MB)
Fostering China Pharmaceutical Innovation System Report 1: 2015-2020 Review and Future Outlook
2021.11
Download
(1.84MB)
Building a System for Pharmaceutical Innovation in China Series Report 3: Multi-Layer Medical Security System to Improve People's Health and Drive High-quality Industry Development
2021.11
Download
(2.55MB)
Fostering China Pharmaceutical Innovation System Series Report 2: Activating the Source of Innovation: Investing in the Basic Research
2021.11
Download
(3.52MB)
Surging Industry Vitality Originated from China's Biomedical City Innovation Map
2021.11
Download
(9.96MB)
Research on Local Implementation of National Reimbursement Negotiated Drugs in China
2021.04
Download
(4.44MB)
Improving the Evaluation Framework of NRDL Dynamic Update for Innovative Drugs in China
2020.11
Download
(2.10MB)
Visioning the Next Ten Years from the Standpoint As a Second Tier Country of Drug Innovation
2020.08
Download
(1.4MB)
The FACES of INNOVATION Meeting the Challenge of chronic respiratory diseases
2021.11
Download
(9.19MB)
Improving Patient Access to Innovative Medicines for a Healthier China 2018
2018.01
Download
(5.73MB)
Building a World-Class Innovative Therapeutic Biologics Industry in China 2014
2014.01
Download
(1.00MB)
